Abstract: This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-? receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
December 20, 2022
Assignee:
RELINIA, INC.
Inventors:
David C Foster, Lutz B Giebel, Leonard G Presta
Abstract: This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-? receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
Type:
Application
Filed:
June 5, 2018
Publication date:
November 26, 2020
Applicant:
Relinia, Inc.
Inventors:
David C Foster, Lutz B Giebel, Leonard G Presta